The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment by Mohammad Farhad, Annah S. Rolig, William L. Redmond

Get full text

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA by William L. Redmond, Melissa J. Kasiewicz, Emmanuel T. Akporiaye

Get full text

Editorial: Advances in Combination Tumor Immunotherapy by Michael A Curran, Bernard A Fox, William L. Redmond

Get full text

OX40 agonists and combination immunotherapy: putting the pedal to the metal by Stefanie N Linch, Michael J McNamara, William L. Redmond

Get full text

Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression. by William L Redmond, Todd Triplett, Kevin Floyd, Andrew D Weinberg

Get full text

Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers. by Zhaoyu Sun, Richard Nyberg, Yaping Wu, Brady Bernard, William L Redmond

Get full text

1360 Treatment with a novel hexavalent OX40 agonist remodels the tumor microenvironment to favor anti-tumor immunity in mice by William L Redmond, Melissa Kasiewicz, Annah Rolig, Yaiza Diaz De Durana, Rashi Yadav

Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT by William L Redmond, Annah S Rolig, Daniel C Rose, Saul Kivimae, Werner Rubas, Grace Helen McGee

Get full text

142 Detection of KRAS G12D/G12V neoepitopes expressed by cancer cell lines using LC-MS/MS by William L Redmond, Bernard A Fox, Eric Tran, Yoshinobu Koguchi, Brian Piening, Noriko Iwamoto, Takashi Shimada, Yuriko Minegishi, Koji Ueda

Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity by Elizabeth R. Sturgill, Annah S. Rolig, Stefanie N. Linch, Courtney Mick, Melissa J. Kasiewicz, Zhaoyu Sun, Peter G. Traber, Harold Shlevin, William L. Redmond

Get full text

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab by William L Redmond, Walter J Urba, John Cha, Yoshinobu Koguchi, Brendan D Curti, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, Brian D Piening

Get full text

149 Simultaneous identification of KRAS mutation-carrying multiple neoepitopes by differential ion mobility-assisted targeted-mass spectrometry by William L Redmond, Bernard A Fox, Eric Tran, Yoshinobu Koguchi, Brian Piening, Noriko Iwamoto, Takashi Shimada, Yuriko Minegishi, Koji Ueda, Kazuma Kiyotani, Satoshi Nagayama

The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor. by Marka R Crittenden, Talicia Savage, Benjamin Cottam, Keith S Bahjat, William L Redmond, Shelly Bambina, Melissa Kasiewicz, Pippa Newell, Andrew M Jackson, Michael J Gough

Get full text

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor by William L Redmond, Yoshinobu Koguchi, Annah S Rolig, Noriko Iwamoto, Takashi Shimada, Elizabeth R Sturgill, Zhaoyu Sun, Venkatesh Rajamanickam, Brady Bernard, Peter G Traber, Eliezer Zomer, J Rex Horton, Harold Shlevin

Get full text

763 Initial results from phase I dose escalation trial of CAN1012 in patients with solid tumor malignancies by Ning Li, William L Redmond, Brendan Curti, Shuhang Wang, Herui Yao, Erwei Song, Henry Yu, Giorgio Massimini, Ming-Hong Hu, Rongliang Lou, Wanping Geng, Sanlong Wang, Meiling Zhang, Rongchu Chen, Baotian Qin, John Mao, Shaoshan Wang

148 Characterizing cancer’s dark matter, short-lived proteins, and defective ribosomal products, presented by cancer and contained in the DPV-001 cancer vaccine by William L Redmond, Bernard A Fox, Tarsem Moudgil, Carlo Bifulco, Walter J Urba, Hong-Ming Hu, Traci Hilton, Yoshinobu Koguchi, Rom S Leidner, Shawn M Jensen, Rachel E Sanborn, Brian Piening, Noriko Iwamoto, Takashi Shimada, Venkatesh Rajamanickam, Yuriko Minegishi, Ryan Meng, Tanisha Christie, Alexa Dowdell, R Bryan Bell, Koji Ueda

A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer by David B. Page, Joanna Pucilowska, Brie Chun, Isaac Kim, Katherine Sanchez, Nicole Moxon, Staci Mellinger, Yaping Wu, Yoshinobu Koguchi, Valerie Conrad, William L. Redmond, Maritza Martel, Zhaoyu Sun, Mary B. Campbell, Alison Conlin, Anupama Acheson, Reva Basho, Philomena McAndrew, Mary El-Masry, Dorothy Park, Laura Bennetts, Robert S. Seitz, Tyler J. Nielsen, Kimberly McGregor, Venkatesh Rajamanickam, Brady Bernard, Walter J. Urba, Heather L. McArthur

Get full text

680 Multi-parametric assessment of the immune response to a trio immunotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma by William L Redmond, Bernard A Fox, Tarsem Moudgil, Carlo Bifulco, Walter J Urba, Christopher Paustian, Hong-Ming Hu, Traci Hilton, Tyler Hulett, Yoshinobu Koguchi, Rom S Leidner, Shawn M Jensen, Brian Piening, Matthew H Taylor, Noriko Iwamoto, Takashi Shimada, Marcus Couey, Venkatesh Rajamanickam, Brady Bernard, Yuriko Minegishi, Lessli Rushforth, Ryan Meng, Tanisha Christie, R Bryan Bell, Koji Ueda, Noah Simons, Annie Stadum, Quyen Vu, Abigail Peterson